Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745335 | 0.92 | PPARD (0.41) | PPARDPPARGPPARABCHE | |
| SCHEMBL1744702 | 0.82 | PPARD (0.54) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL1746767 | 0.80 | ALDH1A1 (0.44) | — | |
| SCHEMBL1747398 | 0.79 | PPARD (0.54) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL1996517 | 0.76 | FFAR1 (0.54) | PPARDPPARGFFAR1FFAR4AKR1B1 | |
| SCHEMBL1745418 | 0.76 | FFAR1 (0.64) | FFAR1FFAR4AKR1B1BCHE | |
| SCHEMBL1745053 | 0.75 | FFAR1 (0.53) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL1745514 | 0.75 | PPARD (0.46) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL3920051 | 0.73 | PPARD (0.55) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL3911218 | 0.71 | FFAR1 (0.54) | PPARDPPARGPPARAFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | PPARD 48/4885PPARG 38/4885PPARA 45/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | PPARD 326/4885PPARG 225/4885PPARA 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.